15 studies found for:    GDC-0941
Show Display Options
Rank Status Study
1 Completed A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
Condition: Healthy Volunteer
Interventions: Drug: GDC-0941;   Drug: ketoconazole
2 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
3 Completed A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: GDC-0941;   Drug: rabeprazole
4 Completed A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0941
5 Recruiting Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Condition: Breast Cancer
Interventions: Drug: GDC-0941;   Drug: placebo;   Drug: fulvestrant;   Drug: GDC-0980
6 Completed A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Cancers
Interventions: Drug: GDC-0941;   Drug: GDC-0973/XL518
7 Completed A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Condition: Solid Cancers
Intervention: Drug: GDC-0941
8 Completed Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects
Condition: Healthy Volunteer
Intervention: Drug: GDC-0941
9 Active, not recruiting A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: GDC-0941;   Drug: Placebo;   Drug: paclitaxel
10 Completed Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Condition: Metastatic Breast Cancer
Interventions: Drug: GDC-0941;   Drug: trastuzumab-MCC-DM1;   Drug: Trastuzumab
11 Recruiting Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
12 Completed A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab;   Drug: carboplatin;   Drug: GDC-0941;   Drug: paclitaxel;   Drug: pemetrexed;   Drug: cisplatin
13 Active, not recruiting A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
Condition: Non-Small Cell Lung Cancer, Solid Cancers
Interventions: Drug: erlotinib HCl;   Drug: GDC-0941
14 Completed A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Condition: Non-Hodgkin's Lymphoma, Solid Cancers
Intervention: Drug: GDC-0941
15 Active, not recruiting A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer
Condition: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Drug: trastuzumab;   Drug: bevacizumab;   Drug: GDC-0941;   Drug: paclitaxel

Indicates status has not been verified in more than two years